

TABLE OF CONTENTS

| | |
|---|--------------|
| ACKNOWLEDGEMENTS (Agradecimientos) | VII |
| THESIS OUTLINE | XI |
| Abstract | xi |
| Resumen | xiv |
| Resum | xvii |
| TABLE OF CONTENTS | XXI |
| LIST OF FIGURES | XXV |
| LIST OF TABLES..... | XXVII |
| ABBREVIATIONS | XXIX |
| GENERAL INTRODUCTION | 1 |
| 1. The ear | 2 |
| 1.1 The cochlea | 3 |
| 1.2 Mechanotransduction and hearing..... | 3 |
| 1.3 The vestibular system | 4 |
| 1.4 Hearing loss..... | 6 |
| 1.5 Vestibular dysfunctions..... | 8 |
| 2. The eye | 8 |
| 2.1 The retina | 8 |
| 2.2 Phototransduction..... | 10 |
| 2.3 Inherited retinal dystrophies..... | 11 |
| 3. Usher syndrome..... | 12 |
| 3.1 Clinical manifestations of Usher syndrome | 13 |
| 3.2 Genetics of Usher syndrome | 14 |
| 3.2.1 Genes involved in Usher syndrome type 1 | 15 |

| | |
|--|-----------|
| <i>MYO7A</i> | 15 |
| <i>USH1C</i> | 16 |
| <i>CDH23</i> | 16 |
| <i>PCDH15</i> | 17 |
| <i>USH1G</i> | 17 |
| <i>CIB2</i> | 18 |
| 3.2.2 Genes involved in Usher syndrome type 2 | 18 |
| <i>USH2A</i> | 18 |
| <i>ADGRV1</i> | 19 |
| <i>WHRN</i> | 19 |
| 3.2.3 Genes involved in Usher syndrome type 3 | 20 |
| <i>CLRN1</i> | 20 |
| 3.2.4 The USH interactome..... | 22 |
| 3.3 Molecular diagnosis of Usher syndrome..... | 24 |
| 3.3.1 Genetic etiology determination..... | 24 |
| 3.3.2 HTS and its application to USH diagnostics | 25 |
| 3.4 Therapeutic approaches for Usher syndrome | 27 |
| 3.4.1 Pharmacological approaches | 27 |
| 3.4.2 Gene therapies | 28 |
| 3.4.2.1 Gene augmentation therapies | 29 |
| 3.4.2.2 Antisense Oligonucleotides..... | 30 |
| 3.4.2.3 Gene editing | 31 |
| 3.4.3 Cell therapy | 31 |
| 3.4.4 Prosthetic systems | 33 |
| 3.4.5 Optogenetic strategies | 33 |
| THESIS OBJECTIVES | 39 |
| CHAPTER I: <i>USH2A</i> gene editing using the CRISPR system..... | 41 |
| Abstract | 42 |
| Introduction..... | 43 |
| Results..... | 45 |
| Discussion | 51 |
| Materials and Methods..... | 55 |

| | |
|---|-----|
| CHAPTER II: <i>HTS for the molecular diagnosis of USH</i> | 63 |
| Abstract | 64 |
| Introduction..... | 65 |
| Methods..... | 66 |
| Results..... | 73 |
| Discussion | 85 |
| | |
| CHAPTER III: <i>Expanding the genetic landscape of Usher-like phenotypes</i> | 91 |
| Abstract | 92 |
| Introduction..... | 93 |
| Methods..... | 94 |
| Results..... | 97 |
| Discussion | 103 |
| | |
| GENERAL DISCUSSION | 112 |
| Apropos the CRISPR-based edition approach..... | 112 |
| Cas9 engineered modifications for increased on-target specificity..... | 113 |
| The matter of NHEJ offshoots and predominance over | 115 |
| Towards knock-in enhancement | 115 |
| Reaching the target organ..... | 117 |
| Cas9 human immunogenicity | 118 |
| | |
| On the subject of the HTS venture..... | 120 |
| The enigma of the USH unsolved cases | 121 |
| The importance of an accurate clinical assessment | 122 |
| Reconsidering past and future USH genetic disclosures..... | 123 |
| | |
| CONCLUSIONS | 128 |
| | |
| APPENDIX | 132 |
| Supplementary information appertaining Chapter II | 132 |
| Supplementary information appertaining Chapter III | 134 |
| | |
| REFERENCES | 140 |